Scholarlink

<p>Ranitidine is an H2-receptor antagonist used to control acid disorders in the gastrointestinal tract. But the long-term use of ranitidine is related to liver dysfunction, which may alter bilirubin levels and disrupt lipid metabolism. Bilirubin, beyond being a liver function marker, plays a role against oxidative stress and lipid dysregulation. In this research, we set out to study the toxic outcomes of ranitidine in selected biochemical parameters with emphasis on the biochemical relationship between bilirubin dysregulation and lipid disturbances and to evaluate the therapeutic potential of capsiate in counteracting this disturbed relationship. The rats are grouped as follows: control, ranitidine-treated, capsiate-treated, and a combination of ranitidine with capsiate-treated group. Capsiate and ranitidine were orally given at doses of (60&#xa0;mg/kg.b.wt and 300&#xa0;mg/kg.b.wt, respectively). Body weight gain and liver weights and relative liver weights; serum levels of direct bilirubin, lipids, glucose, hematological parameters, electrolytes, and comet assay results were evaluated. Ranitidine causes metabolic disturbances, linked with bilirubin, lipids, and glucose regulation, and other biochemical assessments as well as genotoxicity. These findings give new insights about the biochemical link between bilirubin and lipid disturbances in ranitidine-induced liver alterations. On the other hand, capsiate mitigates the biochemical disturbances, genotoxicity, and modulate the disturbed relationship between bilirubin and lipids. The efficacy of capsiate to modulate these disturbances positions it as a promising candidate for future therapeutic applications.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Biochemical disturbances caused by ranitidine in rats: attention to bilirubin–lipids relation and benefits of capsiate

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月3日

查看全文
  • Nawal Z. Haggag,
  • Nora E. M. Shaheen,
  • Amal A. Shahin,
  • Eman S. Elhadidi,
  • Eman A. Sherif

摘要

Ranitidine is an H2-receptor antagonist used to control acid disorders in the gastrointestinal tract. But the long-term use of ranitidine is related to liver dysfunction, which may alter bilirubin levels and disrupt lipid metabolism. Bilirubin, beyond being a liver function marker, plays a role against oxidative stress and lipid dysregulation. In this research, we set out to study the toxic outcomes of ranitidine in selected biochemical parameters with emphasis on the biochemical relationship between bilirubin dysregulation and lipid disturbances and to evaluate the therapeutic potential of capsiate in counteracting this disturbed relationship. The rats are grouped as follows: control, ranitidine-treated, capsiate-treated, and a combination of ranitidine with capsiate-treated group. Capsiate and ranitidine were orally given at doses of (60 mg/kg.b.wt and 300 mg/kg.b.wt, respectively). Body weight gain and liver weights and relative liver weights; serum levels of direct bilirubin, lipids, glucose, hematological parameters, electrolytes, and comet assay results were evaluated. Ranitidine causes metabolic disturbances, linked with bilirubin, lipids, and glucose regulation, and other biochemical assessments as well as genotoxicity. These findings give new insights about the biochemical link between bilirubin and lipid disturbances in ranitidine-induced liver alterations. On the other hand, capsiate mitigates the biochemical disturbances, genotoxicity, and modulate the disturbed relationship between bilirubin and lipids. The efficacy of capsiate to modulate these disturbances positions it as a promising candidate for future therapeutic applications.

Graphical abstract